Abstract
Opicapone (OPC) proved effective in treating end-of-dose motor fluctuations in Parkinson's disease (PD) patients in two large trials. The OPTIPARK study evaluated OPC 50 mg in a heterogeneous patient population treated in real-world conditions. Data from OPTIPARK were used to assess the influence of OPC treatment on the costs for the care of PD patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
